AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18353631
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy with chemotherapy
Trial: 24440473
Drug: Neoadjuvant radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiotherapy and chemotherapy
Trial: 19597863
Drug: Subcutaneous TBA
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous TBA (Group A)
Trial: 15362015
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (weekly individual sessions for four months)
Trial: 2252123
Drug: Three-drug sequential
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug sequential immunosuppression (Minnesota antilymphocyte globulin, prednisone, azathioprine, and cyclosporine) (n = 107)
Trial: 7027747
Drug: Glucose-insulin-potassium-albumin (GIKA)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium-albumin (GIKA) infusion
Trial: 7027747
Drug: 5.5% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5% glucose infusion (Control)
Trial: 31072867
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy
Trial: 25566977
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of piperacillin (PIPC) administered intravenously immediately after endotracheal intubation (Group A)
Trial: 25566977
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cefazolin (CEZ) administered intravenously immediately after endotracheal intubation (Group B)
Trial: 19714296
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Enzastaurin (GE); E 500 mg p.o. daily; loading-dose (1200 mg; Day 1 Cycle 1 only) and G 1000 mg/m2 i.v. Days 1, 8, and 15 in 28-day cycles
Trial: 19714296
Drug: Single-agent Gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent Gemcitabine (G); G as in GE
Trial: 18059013
Drug: Trachea spray
RxNorm normalized name: bovine type II collagen (tracheal cartilage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trachea spray
Trial: 16824841
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg rPSGL-Ig
Trial: 16824841
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg rPSGL-Ig
Trial: 10685789
Drug: cA2 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 monoclonal antibody (1 mg/kg or 10 mg/kg)
Trial: 10685789
Drug: cA2 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 monoclonal antibody (3 mg/kg or 10 mg/kg)
Trial: 31335316
Drug: Extended 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended 16 week course of prednisolone (total dose 3150 mg/m2)
Trial: 31335316
Drug: Standard 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 8 week course of prednisolone (total dose 2240 mg/m2)
Trial: 16492212
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin + unmodified human insulin
Trial: 14586797
Drug: Clodronate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (300 mg intravenous infusion every 3 weeks for 2 years)
Trial: 3192670
Drug: Structured play
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured play therapy approach to the child
Trial: 1550076
Drug: Cyclic PAC
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic PAC chemotherapy
Trial: 1550076
Drug: Brief PAC
RxNorm normalized name: PAC-113
DrugBank: PAC-113 (DB05756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief PAC chemotherapy
Trial: 8591078
Drug: FAM chemotherapy
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM chemotherapy
Trial: 1550076
Drug: Cyclic PAC
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic PAC chemotherapy (Stage III or IV)
Trial: 1550076
Drug: Brief PAC
RxNorm normalized name: PAC-113
DrugBank: PAC-113 (DB05756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief PAC chemotherapy (Stage III or IV)
Trial: 1550076
Drug: FAM chemotherapy
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM chemotherapy (Stage III or IV)
Trial: 27714758
Drug: Ultrasound-guided fascia
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided fascia iliaca block with 2 mg.kg-1 levobupivacaine
Trial: 27402726
Drug: Odanacatib 10
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 10 mg
Trial: 20238255
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of oxytocin infusion was 0.4 IU.min(‐1)
Trial: 17512704
Drug: Cefuroxime 250
RxNorm normalized name: cefuroxime 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 250 mg twice daily
Trial: 2281247
Drug: GHB (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (25 mg/kg h.s. and 3 h later)
Trial: 7330791
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aminophylline and salbutamol
Trial: 25001020
Drug: Dydrogesterone (oral)
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (oral)
Trial: 9815742
Drug: Acyclic retinoid
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclic retinoid (600 mg daily)
Trial: 14976862
Drug: Guideline-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based intervention (early echocardiography, aggressive diuretic therapy, comprehensive education, prescribed diet, intensive pharmacological therapy)
Trial: 9329979
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant growth hormone (hrGH, 6 mg/d for 2 wk)
Trial: 9329979
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant growth hormone (hrGH)
Trial: 8492725
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of hydrocortisone combined with 200 mL saline
Trial: 20637970
Drug: Avanafil 200
RxNorm normalized name: avanafil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil 200 mg
Trial: 29744791
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard antiemetic therapy without olanzapine)
Trial: 22797645
Drug: 700-mg silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700-mg silymarin
Trial: 20368561
Drug: Subsequent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapy (VMP)
Trial: 20368561
Drug: Subsequent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapy (MP)
Trial: 12455305
Drug: Lidocaine patches
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patches applied every 24 hours (group 1)
Trial: 12455305
Drug: Lidocaine patches
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patches applied every 12 hours (group 2)
Trial: 24393781
Drug: Robotic locomotor
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic locomotor training plus overground therapy (LKOGT) for 60 minutes, 5 days per week for 8 weeks.
Trial: 15589440
Drug: Comprehensive spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive spa therapy program for 21 days
Trial: 29447778
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day atorvastatin
Trial: 17047615
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day atorvastatin
Trial: 17955648
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus TCM medication
Trial: 16096518
Drug: Risperidone (0.01-0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.01-0.06 mg/kg/day)
Trial: 26239831
Drug: High-protein breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein breakfast (HP) - 35 g protein, 1,464 kJ
Trial: 26239831
Drug: Normal-protein breakfast
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein breakfast (NP) - 13 g protein, 1,464 kJ
Trial: 9377610
Drug: Nabumetone 1500
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone 1500 mg QD
Trial: 10090436
Drug: Nabumetone 1000
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1000 mg QD
Trial: 7377748
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfadiazine (SD) 250 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Trial: 7377748
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfamethoxazole (SM) 800 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Trial: 21542988
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at an initial dose of 10 ppm
Trial: 18711765
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine therapy (WM)
Trial: 9548155
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human FSH administered before the onset of the menstrual period (experimental group)
Trial: 9548155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (FSH administered in the early follicular phase after the onset of menses)
Trial: 19210650
Drug: Tiotropium, 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium, 18 microg once daily
Trial: 19210650
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg) plus Fluticasone (200 microg), twice daily
Trial: 15605005
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection plus bipolar probe coagulation
Trial: 24762631
Drug: Daily number
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily number of bowel movements
Trial: 24621933
Drug: Amlodipine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (target dose: 10 mg/d)
Trial: 20148263
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of MMRV vaccine
Trial: 20148263
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of MMRV vaccine
Trial: 9082344
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1000 ml 0.16 M NaCl at 16.7 ml/min for 1 hour (induced hypervolemia)
Trial: 9082344
Drug: Standard conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conditions (before infusion)
Trial: 2049965
Drug: Intravenous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or oral ofloxacin
Trial: 9921995
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin
Trial: 19461006
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 soft-gel pills, no active ingredients)
Trial: 15657476
Drug: TCAI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCAI group (multinutrient supplement containing TCAIs)
Trial: 11697813
Drug: Short-chain fructo-oligosaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain fructo-oligosaccharides (sc-FOSs) 10 g/day
Trial: 9390050
Drug: 568 ml
RxNorm normalized name: petrolatum 568 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 568 ml (one pint) of whole or reduced fat milk per day for 18 months
Trial: 9390050
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (baseline average milk intake 150 ml)
Trial: 29282259
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (6-month weekly exercise program, 60 min, two times a week)
Trial: 22585232
Drug: THC 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 7.5 mg
Trial: 9379341
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Trial: 11462311
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy after a 12-week period with enhanced compliance to diet and oral therapy
Trial: 11462311
Drug: Enhanced compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enhanced compliance to diet and oral therapy (control group)
Trial: 9787691
Drug: Depo-testosterone (to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-testosterone (to boys) or conjugated estrogens (to girls) administered in 3-month blocks, alternating with placebo, at 3 dose levels.
Trial: 9787691
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) administered in 3-month blocks, alternating with Depo-testosterone or conjugated estrogens.
Trial: 1975522
Drug: Heparin in
RxNorm normalized name: heparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin in conjunction with aspirin and a thrombolytic agent
Trial: 896123
Drug: Adriamycin (20‐25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (20‐25 mg/m2/day for three days each three weeks)
Trial: 31188260
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for intra-articular DRF based on patient factors such as younger age, clinically significant fracture displacement, normal activity level, and high-energy mechanisms.
Trial: 31188260
Drug: Treatment decisions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment decisions rated by AUC recommendations.
Trial: 19140167
Drug: 5-[(123)I]IA administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-[(123)I]IA administered intravenously at approximately 0.001 microg/kg (approximately 10 mCi)
Trial: 11829098
Drug: Formoterol (Oxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (Oxis Turbuhaler; 90 microg delivered dose; 120 microg metered dose)
Trial: 11829098
Drug: Terbutaline (Bricanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (Bricanyl Turbuhaler; 10 mg)
Trial: 2178939
Drug: Doxorubicin weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin weekly for 6 weeks followed by no further treatment (short-term regimen)
Trial: 2178939
Drug: Doxorubicin weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin weekly for 6 weeks followed by monthly instillation for 2 years (long-term regimen)
Trial: 72901
Drug: beta-blocker plus
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker plus indomethacin (100 mg daily)
Trial: 72901
Drug: beta-blocker alone
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker alone (last phase)
Trial: 28420471
Drug: Pv‐aCO2 combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pv‐aCO2 combined with PLR directed therapy
Trial: 28420471
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous pressure (CVP) directed therapy
Trial: 22092589
Drug: NobelActive(TM) implant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NobelActive(TM) implant
Trial: 22092589
Drug: Brånemark implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implant
Trial: 10224729
Drug: Combined Treatment
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Treatment (PE-SIT)
Trial: 8722217
Drug: Alpha-tocopherol 60
RxNorm normalized name: (+)-alpha-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol 60 mg/day
Trial: 8722217
Drug: Alpha-tocopherol 200
RxNorm normalized name: (+)-alpha-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol 200 mg/day
Trial: 1848679
Drug: Prophylactic ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic ganciclovir (5 mg/kg IV twice daily for two weeks, then five times per week until day 120)
Trial: 22805300
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g fibrinogen concentrate
Trial: 3828182
Drug: No infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No infusion (control group)
Trial: 19850684
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogens (CEE) daily
Trial: 12932748
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (Genotropin, Pharmacia) starting at 0.8 IU for one month, then 1.6 IU for 5 months, followed by individual titration to normal levels for age.
Trial: 17280527
Drug: Placebo treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment.
Trial: 11101059
Drug: Twice-daily stavudine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily stavudine (40 mg) plus once-daily didanosine (400 mg) and nevirapine (400 mg)
Trial: 11101059
Drug: Twice-daily stavudine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily stavudine (40 mg) plus twice-daily didanosine (200 mg) and nevirapine (200 mg)
Trial: 8985029
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and razoxane (150 mg/m2 daily during radiotherapy, starting 5 days before first irradiation)
Trial: 1728731
Drug: Perioperative antibiotics
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotics
Trial: 9923817
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron daily plus 300 mg cimetidine four times daily
Trial: 9923817
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron daily plus 600 mg rifampin daily
Trial: 9923817
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron daily (control)
Trial: 2254674
Drug: Ketanserin (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20‐40 mg three times a day)
Trial: 31948475
Drug: Jianpishengsui (JPSS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpishengsui (JPSS) herbal formula cream